Condition: Tuberculosis · HIV · Sponsor: Johns Hopkins University
This will be a Phase IIIb Clinical Trial, an international multicenter, randomized, three-arm, non-comparative trial of efficacy, safety, and tolerability of the dual therapy regimen dolutegravir plus lamivudine either twice daily or DTG/3TC ( Dovato) in the morning +dolutegravir (DTG) in the evening, versus standard of care (SOC) twice-daily dolutegravir plus 2 once-daily Nucleoside reverse-transcriptase inhibitors (NRTIs) tenofovir disoproxil fumarate /lamivudine (TDF/3TC), among antiretroviral therapy (ART)-nave individuals with HIV-1 receiving rifampin-based TB therapy
This description comes directly from the study's public registry record.
Beatriz M Kohler, RN · 410 614 3812 · bkohler@jhmi.edu
Kate Boehner, RN · kboehne1@jh.edu
Always discuss trial participation with your own doctor first.
| Instituto Tropical de Doenças Infecciosas Manaus | Manaus, Amazonas, Brazil | Recruiting |
| Universidade Federal da Bahia | Salvador, Estado de Bahia, Brazil | Recruiting |
| FIOCruz | Rio de Janeiro, Rio de Janeiro, Brazil | Recruiting |
| Hospital Geral de Nova Iguaçu | Rio de Janeiro, Rio de Janeiro, Brazil | Recruiting |
| CePClin - Center for Studies and Research in Infectious Diseases Ltda | Natal, Rio Grande do Norte, Brazil | Recruiting |
| RDSS- Ricardo Diaz Solucoes Cientificas | São Paulo, São Paulo, Brazil | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06497465